Stay updated with breaking news from Double Blinded Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.
Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.
/PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy,...
Study Aims to Assess Safety and Efficacy of BXQ-350 in Combination with Standard of Care for mCRCCOVINGTON, Ky., Jan. 10, 2023 /PRNewswire/ -- Bex...